Molecular Partners (DB:6ML0) - Stock Price, News & Analysis

6ML0 Stock Overview

A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. More details

6ML0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 57.83% per year

Risk Analysis

Earnings are forecast to decline by an average of 1.2% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Molecular Partners AG Competitors

Heidelberg Pharma

XTRA:HPHA

€103.9m

Medigene

XTRA:MDG1

€22.6m

Formycon

XTRA:FYB

€827.2m

Biotest

XTRA:BIO3

€1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Molecular Partners
Historical stock prices
Current Share Price	CHF 5.00
52 Week High	CHF 10.60
52 Week Low	CHF 3.00
Beta	0.54
11 Month Change	-15.25%
3 Month Change	-15.25%
1 Year Change	n/a
33 Year Change	-51.92%
5 Year Change	n/a
Change since IPO	-67.86%

Recent updates

Shareholder Returns

	6ML0	DE Biotechs	DE Market
7D	-3.8%	-0.7%	0.2%
1Y	n/a	-17.2%	8.5%

Return vs Industry: Insufficient data to determine how 6ML0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 6ML0 performed against the German Market.

Price Volatility

Is 6ML0's price volatile compared to industry and market?
6ML0 volatility
6ML0 Average Weekly Movement	14.5%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 6ML0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6ML0's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2004	162	Patrick Amstutz	www.molecularpartners.com

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.

Molecular Partners AG Fundamentals Summary

How do Molecular Partners's earnings and revenue compare to its market cap?
6ML0 fundamental statistics
Market cap	€192.00m
Earnings (TTM)	-€67.22m
Revenue (TTM)	€6.45m

29.8x

P/S Ratio

-2.9x

P/E Ratio

Is 6ML0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6ML0 income statement (TTM)
Revenue	CHF 6.00m
Cost of Revenue	CHF 49.97m
Gross Profit	-CHF 43.96m
Other Expenses	CHF 18.63m
Earnings	-CHF 62.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.70
Gross Margin	-732.47%
Net Profit Margin	-1,042.84%
Debt/Equity Ratio	0%

How did 6ML0 perform over the long term?

See historical performance and comparison

Molecular Partners DB:6ML0 Stock Report